Regulation of therapeutic goods in the United States |
---|
![]() |
Prescription drugs Over-the-counter drugs |
The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. Regulations are primarily at 21 CFR 312. Similar procedures are followed in the European Union, Japan, and Canada due to regulatory harmonization efforts by the International Council for Harmonisation.[1]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search